Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03206957
Other study ID # P2017/Ophtalmo/DOPANUR
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 30, 2017
Est. completion date June 1, 2019

Study information

Verified date July 2018
Source Queen Fabiola Children's University Hospital
Contact Lavina Postolache, MD
Phone 0032 2 477 21 92
Email lavina.postolache@huderf.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In approximately half of individuals with Down syndrome, an higher than normal number of vessels cross the optic disc margin. Investigator hypothesize that early retinal vessel branching occurs due to inhibition of angiogenesis by triplet overexpression of endostatin, an angiogenesis inhibitor encoded on chromosome 21. Since angiogenesis is critical in the development of eyes and other organs angiogenesis depended (specially kidney, brain, and recently described lungs and heart), early branching of retinal vessels at the level of the optic disc would also likely result in abnormal renal and other organs development in these individuals. Investigator wish to determine whether observation of optic disc vessels may serve as an indicator of elevated endostatin levels and other angiogenesis-dependent organs anomalies.


Description:

Investigator will measure the serum levels of endostatin as well as others angiogenetic factors in Down syndrome children versus control group 1 constituted by the patient mothers.

Investigator will also perform renal and low urinary tract Doppler ultrasound with measurement of renal dimension in order to determine if the kidneys of patients with high level of serum of endostatin are smaller than those of patients with normal level of endostatin. Data observed in Down syndrome children will be compared to control group 2age constituted by sex and age matched healthy children Urine microalbuminuria and urine microalbuminuria/creatinuria from the first urine in the morning will be evaluated.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date June 1, 2019
Est. primary completion date June 1, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 17 Years
Eligibility Inclusion Criteria:

- Provision of personally signed and dated informed consent document by adult subject or parents

- When capable of providing assent, provision of personally signed and dated informed assent document by children

- Subjects and/or their caregivers/parents are willing and able to comply with scheduled laboratory tests, and other required study procedures.

Exclusion Criteria:

• Inability to cooperate with study related examination

For "Study Group" subjects

- Known chronic diseases unrelated to their triallelic condition For "Control Group n°1" & "Control Group n°3"

- General disease in which the level of endostatin may be modified such as leukemia, cancers, inflammatory diseases (e.g.: rheumatoid arthritis, Crohn's disease, psoriasis)

- Any condition that may cause a hypoxia

- Pregnancy

For "Control Group n°2":

- Healthy children except benign ophthalmological refraction anomalies

- Any known renal or low urinary tract diseases.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Funduscopic examination and retinal photography
A standardized funduscopic examination and retinal photography will be performed by an ophthalmologist focusing on optic nerve.
Serum levels of endostatin and angiogenesis factors
Serum levels of endostatin, angiopoietin and vaso endothelial growth factor will be analyzed
Renal and low urinary tract Doppler ultrasound
Measurements of each kidney will include maximum renal bipolar length in a sagittal plane, renal width and thickness in an axial plane perpendicular to each other at the level of renal hilum and cortical thickness. Intensity of corticomedullary differentiation will estimated. Doppler ultrasound examination will assess renal arterial resistivity indexes
Urinalysis
Urinalysis assessments will include assessments of microalbuminuria and microalbuminuria to creatinuria ratio. A spot urine sample will be collected from first morning void.
Anthropometric measures and vitals signs
weight, height and blood pressure will be assessed

Locations

Country Name City State
Belgium Hôpital Universitaire Des Enfants Reine Fabiola Brussels

Sponsors (1)

Lead Sponsor Collaborator
Queen Fabiola Children's University Hospital

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation between the number of retinal vessels crossing the optic disc and serum level of endostatin correlation coefficent 18 months
Secondary Correlation between the number of retinal vessels crossing the optic disc and serum level of other angiogenic factors correlation coefficent 18 months
Secondary Correlation between serum level of endostatin and serum level of other angiogenic factors correlation coefficient 18 months
Secondary Description of renal anomalies in Down syndrome. absolute number and type of renal anomalies 18 months
Secondary Comparison of prevalence of renal anomalies between Down syndrome and healthy subjects Proportion and type of disease 18 months
Secondary Correlation between the number of optic nerve vessels and the presence of organs pathologies correlation coefficient 18 months
Secondary Correlation between serum level of angiogenesis factors and the presence of organs pathologies correlation coefficient 18 months
See also
  Status Clinical Trial Phase
Recruiting NCT04854122 - Blood Flow Regulation in Individuals With Down Syndrome - Training Study N/A
Completed NCT04020302 - Self-Monitoring Shopping Intervention N/A
Recruiting NCT01950624 - DS-Connect {TM}: The Down Syndrome Registry
Completed NCT04751136 - the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome Phase 2
Completed NCT04767412 - Inspiratory Muscle Training and Physical Fitness in Children With Down Syndrome Randomized Control Trial N/A
Not yet recruiting NCT04037579 - Protocol for a Non-randomized Survey in Down Syndrome People Who Practice Sports. Self and Observers´ Perception.
Completed NCT04536506 - Bobath and Vojta Therapy for DS N/A
Completed NCT02882698 - Performance Analysis in Down Syndrome on Mobile Phone N/A
Completed NCT01791725 - A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia Phase 2
Unknown status NCT01975545 - Fluor Varnish With Silver Nanoparticles for Dental Remineralization in Patients With Trisomy 21 Phase 2
Completed NCT01808508 - Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome N/A
Terminated NCT00754052 - Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17 Phase 3
Terminated NCT00754013 - Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10 Phase 3
Completed NCT01256112 - Parent Supported Weight Reduction in Down Syndrome N/A
Completed NCT01313325 - Hippotherapy to Improve the Balance of Children With Movement Disorders N/A
Completed NCT01594346 - Multicenter Vitamin E Trial in Aging Persons With Down Syndrome Phase 3
Completed NCT05343468 - Life Skills Improved in Children With Down Syndrome After Using Assistive Technology N/A
Suspended NCT05755464 - Evaluation of Patients With Down Syndrome Compliance to Dental Therapy
Recruiting NCT04022460 - Using Personal Mobile Technology to Identify Obstructive Sleep Apnea in Children With Down Syndrome (UPLOAD)
Completed NCT04818437 - Effect of Core Stability Exercises and Balance Training in Postural Control Among Down Syndrome N/A